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Abstract Psoralen in conjunction with UVA (PUVA) is
perhaps the most effective treatment for psoriasis. It is, however,
a risk factor for skin cancer in these patients and there is a need
to develop non-invasive assays reflective of treatment-induced
DNA damage. We report here the assessment of two important
lesions, thymine dimer (TGfT) and 8-oxo-2P-deoxyguanosine (8-
OHdG), in the urine of psoriasis patients. It was found that, once
corrected for urine concentration, the psoriatic group had
significantly higher (P6 0.0001) urinary levels of thymine dimers
compared to the control group. No significant differences in
urinary 8-OHdG levels were noted between the psoriatic, atopic
dermatitis and control groups. Therefore biomonitoring of
therapy from the very start with this simple and non-invasive
assay could perhaps be an effective measure of the risk involved
with the treatment allowing optimization for minimal-risk
therapy.
z 1999 Federation of European Biochemical Societies.
Key words: PUVA; 8-Oxo-2P-deoxyguanosine;
Thymine dimer; Psoriasis ; Antibody; Urine
1. Introduction
The major features of psoriasis are abnormal di¡erentiation
and hyperproliferation of keratinocytes, along with in¢ltration
of in£ammatory cells into the skin [1]. About 2% of the
world’s population is a¡ected with psoriasis and it is believed
that immunological factors, abnormal epidermal growth and
abnormal keratinization are of pathogenic relevance [2]. A
variety of treatments are available for psoriasis [3], tradition-
ally aimed at reducing the abnormal epidermal proliferation.
However these treatments are genotoxic and must be consid-
ered potentially carcinogenic [4].
The discovery in 1974 of a new photobiologic principle,
light and drug, paved the way for a new and e¡ective treat-
ment of psoriasis. Psoralens, an important class of compounds
widely distributed in nature [5,6], are used extensively as ther-
apeutic agents for the treatment of skin diseases like psoriasis.
This approach, which combines psoralen with UVA radiation
(PUVA), whilst e¡ective for treating psoriasis has long term
side e¡ects including an increased risk of cutaneous malig-
nancy related, in part, to the cumulative dose of UVA re-
ceived during PUVA therapy [7,8]. It has been suggested
that psoralens owe their photosensitizing and photochemo-
therapeutic e¡ectiveness to their ability to intercalate into
DNA and form psoralen-DNA photoadducts upon subse-
quent exposure to UVA light [9]. Although PUVA therapy
can achieve 80^90% clearance of plaques in 8^12 weeks [10],
this treatment is done on a long term basis to prevent recur-
rence, or to treat new lesions. Such chronic treatment poses a
threat through the development of skin cancer [11]. It is there-
fore essential to develop procedures to increase the safety of
the treatment by predicting and hence minimizing carcinogen-
ic e¡ects.
Progress has been made in understanding the molecular
events of non-melanoma skin cancer, through associating
characteristic UVR-induced mutations at dipyrimidine sites
with DNA photolesions such as cyclobutane pyrimidine
dimers (CPD) and 6-4 photoproducts [12], which are inducible
at clinically relevant doses of UVB and UVA [13]. A major
biomarker of oxidative stress is the DNA damage product 8-
hydroxy-2P-deoxyguanosine [14]. Since reactive oxygen species
(ROS) are assumed to be involved in the pathogenesis of
chronic in£ammatory skin diseases, such as atopic dermatitis,
it is possible that increased ROS generation may be one of the
contributing factors to tissue damage in psoriasis [15]. Indeed,
it has recently been shown that patients with atopic dermatitis
have signi¢cantly higher levels of urinary 8-OHdG [16]. A role
for 8-OHdG in carcinogenesis has been postulated [17] and its
involvement in skin damage is based on evidence that UV-
derived hydroxyl radicals and singlet oxygen induce 8-OHdG
in vitro [18]. Furthermore, high levels of 8-OHdG appear in
normal human epidermis after a single dose of UV radiation
suggesting a signi¢cant role in UV-induced carcinogenesis
[19].
Damaged DNA products are eliminated by a variety of
repair enzymes and may be detected as nucleoside derivatives
[20]. The level of these products depends on the equilibrium
between the rates of damage and repair, re£ected by the
amount of lesion excreted into urine. In the present study
we examined the urine of psoriasis patients post-PUVA treat-
ment for two markers of genotoxic insult : 8-OHdG, an ac-
knowledged marker of oxidative stress and thymine dimer
(TGfT), a unique marker of UV exposure. The measurement
of 8-OHdG was by a competitive ELISA using a speci¢c
monoclonal antibody obtained commercially, whereas TGfT
measurement utilized a polyclonal antiserum raised against
UVC-irradiated poly(dT), characterization of which indicated
speci¢c recognition of TGfT. We predict that the development
of such non-invasive assays to measure oxidative and non-
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oxidative DNA damage may represent a means by which an
individual’s ability to process DNA lesions could be deter-
mined and a therapy-related risk assessment performed.
2. Materials and methods
2.1. UVC irradiation of polythymidylic acid and synthetic
oligonucleotides
Polythymidylic acid was purchased from Sigma Chemical Company
(Poole, UK) and the synthetic oligonucleotides were prepared by the
Protein and Nucleic Acid Laboratory, Department of Biochemistry,
University of Leicester, UK. All irradiations were performed on ice,
using a 254 nm UVC source (Knight Optical Technologies) and given
a total exposure of 21 J/cm2. Proof that TGfT are successfully induced
by UVC irradiation was provided by GC-MS analysis [21].
2.2. Production and puri¢cation of polyclonal antibodies
UVC-irradiated poly(dT) was complexed with methylated bovine
serum albumin (BSA) as described earlier [22]. Each rabbit was immu-
nized according to Cooke et al. [23]. The resulting antiserum was
puri¢ed for IgG class antibodies with a Protein A Sepharose CL-4B
column and the speci¢city evaluated by a competitive binding assay.
2.3. Enzyme-linked immunosorbant assay
The detection of antibodies to UVC-poly(dT) by direct ELISA and
competitive ELISA to de¢ne speci¢city was performed in a manner
similar to that described by Cooke et al. [23], with the knowledge that
damaged and native DNA bind equally well to ELISA plates [24]. In
both instances, UVC-DNA was used as the solid phase antigen,
bound to 96-well ELISA plates (Life Technologies Ltd., Paisley, Scot-
land) and the primary antiserum used diluted 1:5000 in milk/PBS.
Detection of the primary antiserum was by peroxidase-labelled goat
anti-rabbit IgG (DAKO Ltd., High Wycombe, UK) diluted to 1:2000
(in milk/PBS; 50 Wl/well). Absorbances were read at 492 nm using an
Anthos 2001 plate reader (Anthos Labtec Instruments, UK).
2.4. Detection of TGfT in urine
The ability of antiserum to detect TGfT in urine was demonstrated
by ‘spiking’ urine samples with known concentrations of TGfT-con-
taining oligomers prior to analysis by competitive ELISA.
2.5. Urine samples
Urine samples were obtained from a total of 33 patients (21 female,
12 male; median age 36 years, age range 14^85 years), who were
classi¢ed with mild to moderate psoriasis (mean Psoriasis Assessment
Severity Index [PASI] score 8.5; range 1.2 to 17.4). All were on topical
therapy comprising tar and emollients of vitamin D3 analogues. A
control group of 16 subjects was used (10 males and 6 females; me-
dian age 30.7 years, age range 17^43 years). Seven individuals with
atopic dermatitis were also examined as a reference dermatitis group
(three male, four female; median age 38 years, age range 13^74 years),
three of which were assessed as severe or post-£are. The urinary
creatinine values of all the groups were examined (Department of
Chemical Pathology, Leicester Royal In¢rmary, Leicester, UK) as
impaired renal function may a¡ect levels of any lesion excreted into
the urine. Collected urine samples were stored, without any additives,
at 380‡C in 20 ml plastic Universal tubes, until analysis. Following
thawing and centrifugation (300Ug for 10 min), the supernatants were
applied to the competitive ELISA plate according to the protocol
described earlier.
2.6. Urinary 8-OHdG measurements
Samples of urine were analyzed by competitive ELISA, without
prepuri¢cation, using ‘8-OHdG Check’ (JaICA, Fukuroi City, Japan)
[25].
2.7. Urinary thymine dimer measurements
Samples of urine were analyzed by competitive ELISA, without
prepuri¢cation, using the anti-thymine dimer antibody described
above.
Statistical analysis was performed using Graph Pad Prism, version
2.01.
3. Results
The immunogen UVC-poly(dT)/BSA conjugate induced a
strong immunogenic response in rabbits, such that at a
1:5000 dilution of the antibody produced an ELISA absorb-
ance at 492 nm of 1.0 whilst the binding of pre-immune serum
was negligible. Isotyping revealed the majority of the response
to be of the IgG class. The antigenic speci¢city of the anti-
body was determined by a series of competitive ELISA experi-
ments. The concentration of competitor giving 50% inhibition
(IC50) is an index of the antigenicity of the compound and the
lower the value the better the competitor.
UVC-poly(dT) was a very e¡ective inhibitor of antibody
binding with the IC50 less than 0.07 Wg/ml whilst unirradiated
poly(dT) inhibited to a much lesser extent with an IC50 of
13.85 (Table 1). UVC-irradiated DNA, made single-stranded
(ss) was a better inhibitor than double-stranded (ds) UVC-
DNA, whereas no signi¢cant inhibition was observed with
native DNA irrespective of whether single- or double-stranded
(data not shown). Further identi¢cation of epitopes recog-
nized by the antibody was performed with a series of thy-
mine-containing oligonucleotides. Initially the e¡ect of length
of thymidylate oligonucleotides was investigated, with the ef-
fectiveness of inhibition increasing with chain length (Table
1). Furthermore poly(A12), poly(C12) and poly(G12) whether
UVC-irradiated or not, consistently failed to inhibit in the
competition ELISA (Table 1), directly implicating thymine
dimerization in the epitope formation.
In order to con¢rm that adjacent thymine residues are nec-
essary for binding we used a septanucleotide containing alter-
nating A and T residues which was found to be an ine¡ective
inhibitor when UVC-irradiated. Another oligomer of alternat-
ing A-A and T-T units, when UVC-irradiated, also inhibited
poorly implying that dimerization of thymine residues alone
was not su⁄cient to form the preferentially recognized antigen
Fig. 1. Antibody recognition of thymine dimer-containing oligomers
in urine. Urine samples were spiked with increasing concentrations
of oligomer prior to competitive ELISA.
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for the majority of antibodies present in the serum. However,
when a UVC-irradiated oligonucleotide with three thymine
residues in sequence £anked by adenine residues was used, a
strong inhibitory response was seen. This strong recognition
was not improved appreciably by four thymine residues in a
sequence £anked by adenine residues (Table 1). Putative uri-
nary constituents which might interfere with the assay were
also investigated and shown not to inhibit antibody binding
(Table 2). The ability of the antiserum to detect thymine
dimers in urine was further demonstrated by the linearity of
the competitive ELISA response in spiking experiments
(Fig. 1).
Assessment of urinary creatinine concentration indicated
the psoriatic and atopic dermatitis patients to be free from
renal disease and hence this would not a¡ect urinary 8-OHdG
or TGfT levels. Creatinine levels were successfully applied to
correct for urine concentration. No signi¢cant di¡erences in
urinary 8-OHdG levels were noted between the control (9.78,
S.D. = 3.80 pmol/Wmol creatinine), atopic dermatitis (12.29,
S.D. = 7.72 pmol/Wmol creatinine) and psoriasis (9.36,
Fig. 2. Detection of 8-OHdG in the urine samples of patients with psoriasis, using a monoclonal antibody-based competitive ELISA. (Only
n = 29 psoriatic patients are represented as four had urinary levels of 8-OHdG below the limit of detection.) Also represented is the in£amma-
tory disease control, atopic dermatitis patients and healthy control subjects.
Fig. 3. Detection of urinary thymine dimers in psoriasis patients using a polyclonal antiserum-based competitive ELISA. Also represented is
the in£ammatory disease control, atopic dermatitis patients and healthy control subjects.
FEBS 22838 28-10-99
J. Ahmad et al./FEBS Letters 460 (1999) 549^553 551
S.D. = 7.80 pmol/Wmol creatinine) groups (Fig. 2). No corre-
lation was seen between PASI scores and urinary 8-OHdG
(data not shown). Urinary levels of thymine dimer were found
to be signi¢cantly raised in both the psoriasis (P6 0.0001) and
atopic dermatitis (P = 0.007) patients compared to the control
group (Fig. 3).
4. Discussion
PUVA is a highly e¡ective treatment for psoriasis, although
prolonged use is associated with an increased risk of develop-
ing non-melanoma skin cancer, in particular squamous cell
carcinoma [26]. Several studies have shown that psoriasis pa-
tients who receive extensive PUVA therapy have a 10-fold
increase in the incidence of squamous cell carcinoma over
that in the general population [27]. There could be several
explanations for the increased incidence of skin cancer in
PUVA-treated patients. First, PUVA is mutagenic and carci-
nogenic and may itself induce skin cancer [28]. Second, be-
cause PUVA treatment is immunosuppressive [29], it may
permit the growth of skin cancers induced by other carcino-
genic agents. Third, because many psoriasis patients undergo
treatment with UVB (290^320 nm) in addition to PUVA [30]
or because the light sources sometimes used in PUVA therapy
contain small but signi¢cant wavelengths in the UVB region
these might be the inducing carcinogen.
Since UV and PUVA induce di¡erent types of lesion in
DNA, it has been hypothesized that mutations induced by
these agents may also be di¡erent [31]. While UV induces
primarily cyclobutane-type pyrimidine dimers and pyrimidine
(6-4)-pyrimidone photoproducts [32], PUVA induces mono-
functional adducts and DNA cross-links [33]. The main repair
mechanism responsible for the elimination of both types of
DNA lesions is probably nucleotide excision repair (NER)
which removes bulky and helix-distorting lesions from DNA
[34], which are subsequently excreted in the urine. Psoralen is
also known to generate ROS, presumably singlet oxygen,
through type II photodynamic action [35] and it has recently
been hypothesized that PUVA-induced oxidative DNA dam-
age may occur in vivo [36]. Urinary 8-OHdG, derived from
the nucleotide pool or DNA, via an endonuclease or NER is
an accepted marker of oxidative stress [25]. Additionally, cell
turnover, due to apoptosis or necrosis may also contribute to
urinary levels of any lesion but are still re£ective of lesion
levels induced by treatment [37].
Our work represents the ¢rst report of urinary 8-OHdG
measurements in psoriasis and the results suggest that there
is no chronic oxidative stress associated with mild to moderate
forms of this disease. However, oxidative stress may be in-
duced during PUVA treatment, with the assay still applicable
to biomonitoring. Contrary to a recent report [16] we did not
detect elevated levels of 8-OHdG in atopic dermatitis patients
although this may be due to the limited number of subjects
studied.
We have developed a unique assay utilizing a polyclonal
antibody speci¢c for TGfT for the detection of this lesion in
the urine of psoriasis patients. When compared with controls
and once corrected for creatinine and hence urine concentra-
tion, the psoriatic group was found to contain signi¢cantly
higher urinary levels of the lesion, thus suggesting a relation-
ship between its presence and the treatment. Three patients
within the atopic dermatitis group possessed elevated urinary
TGfT, raising the levels for that group to one of signi¢cance.
Examination of these three patients revealed them to be either
particularly severe, or post-£are. UV exposure is routinely
used for treatment of such cases, which would be expected
to generate elevated levels of this lesion. These ¢ndings war-
rant further study of this patient group.
Taken together, these data implicate the UV given to psor-
iasis patients as part of PUVA therapy as the source of thy-
mine dimers in urine. Therefore a constant monitoring of the
treatment for thymine dimers and perhaps 8-OHdG in the
urine may provide a good measure of the risk involved and
aid intervention to provide a minimal-risk therapy.
Table 1
Index of inhibition by a variety of oligonucleotide modi¢ed/native DNA and protein competitors, as determined by competitive ELISA with
the anti-thymine dimer antiserum
Characterization competitor IC50 (Wg/ml)
UVC-poly(dT) 6 0.07
poly(dT) 13.86
T3 UVC-irradiated 19.39
T6 UVC-irradiated 0.74
T9 UVC-irradiated 0.11
TATATAT UVC-irradiated s 50.00
TAATTA UVC-irradiated 17.11
AATTTAA UVC-irradiated 4.64
AATTTTAA UVC-irradiated 3.98
poly(G12) Irradiated/unirradiated s 100.00
poly(C12) Irradiated/unirradiated s 100.00
poly(A12) Irradiated/unirradiated s 100.00
Keyhole limpet haemocyanin s 250
Table 2
Index of inhibition by a variety of putative urinary constituents, as
determined by competitive ELISA with the anti-thymine dimer anti-
serum
Putative urinary constituent IC50 (Wg/ml)
Thymine s 250
Guanine s 250
Cytosine s 250
Adenine s 250
Xanthine s 250
Albumin s 250
Uric acid s 6000
Urea s 6000
Creatinine s 6000
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